Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative

European Journal of Medicinal Chemistry

Volumn 46, Issue 5, 2011, Pages 1656-1664

  Kesel, Andreas J ^a  

^a NONE   (Germany)

Author keywords

HCV Huh7 ET replicon; HCV replicon replication inhibitors; Hepatitis C virus (HCV); HIV 1 inhibitor; Retinoid thiosemicarbazone; Thiosemicarbazone derivatives

Indexed keywords

2 (RETINYLIDENE) N [[2 (RETINYLIDENE)HYDRAZINYL]CARBONOTHIOYL]HYDRAZINECARBOTHIOAMIDE TRISODIUM SALT HEMIHENDECAHYDRATE; 4 (DIMETHYLAMINO)BENZALDEHYDE THIOSEMICARBAZONE; 4 (TRIFLUOROMETHOXY)BENZALDEHYDE THIOSEMICARBAZONE; 4 [[[4 (4 FLUOROPHENYL) 1,3 THIAZOL 2(3H) YLIDENE]HYDRAZINYLIDENE]METHYL] N,N DIMETHYLANILINE HEMIHYDRATE; 4 BROMO 2 FLUOROBENZALDEHYDE THIOSEMICARBAZONE; ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; GANCICLOVIR; RECOMBINANT ALPHA2B INTERFERON; TETRADECYL 4 (DIMETHYLAMINO)BENZALDEHYDE ISOTHIOSEMICARBAZONE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COWPOX VIRUS; DRUG SYNTHESIS; HEPATITIS C VIRUS; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; RNA REPLICATION; THIN LAYER CHROMATOGRAPHY; VACCINIA VIRUS; VARICELLA ZOSTER VIRUS; VIRUS INHIBITION; VIRUS STRAIN;

ANTI-BACTERIAL AGENTS; BENZALDEHYDES; CELL LINE, TUMOR; CHROMATOGRAPHY, THIN LAYER; CYTOMEGALOVIRUS; HEPACIVIRUS; HERPESVIRUS 3, HUMAN; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; RETINOIDS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIOSEMICARBAZONES;

EID: 79953216695     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.02.014     Document Type: Article

References (53)

1. P. Marcellin Hepatitis B and hepatitis C in 2009 Liver Int. 29 s1 2009 1 8
2. T.J. Liang, and T. Heller Pathogenesis of hepatitis C-associated hepatocellular carcinoma Gastroenterology 127 Suppl. 1 2004 S62 S71
3. R.P. Beasley, L.-Y. Hwang, C.-C. Lin, and C.-S. Chien Hepatocellular carcinoma and hepatitis B virus - a prospective study of 22 707 men in Taiwan Lancet 318 II 1981 1129 1133
4. M.-Y. Lai, J.-H. Kao, P.-M. Yang, J.-T. Wang, P.-J. Chen, K.-W. Chan, J.-S. Chu, and D.-S. Chen Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C Gastroenterology 111 1996 1307 1312 (Pubitemid 26362256)
5. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, Z.D. Goodman, M.-H. Ling, S. Cort, J.K. Albrecht for The Hepatitis Interventional Therapy Group Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N. Engl. J. Med. 339 1998 1485 1492 (Pubitemid 28543496)
6. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, F.L. Gonales Jr., D. Häussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N. Engl. J. Med. 347 2002 975 982
7. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, R. Reindollar, Z.D. Goodman, K. Koury, M.-H. Ling, J.K. Albrecht The International Hepatitis Interventional Therapy Group Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
8. D.E. Baker Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C Rev. Gastroenterol. Disord. 3 2003 93 109 (Pubitemid 36701289)
9. D.E. Baker Pegylated interferons Rev. Gastroenterol. Disord. 1 2001 87 99
10. T. Asselah, Y. Benhamou, and P. Marcellin Protease and polymerase inhibitors for the treatment of hepatitis C Liver Int. 29 Suppl. 1 2009 57 67
11. A.D. Kwong, L. McNair, I. Jacobson, and S. George Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors Curr. Opin. Pharmacol. 8 2008 522 531
12. T. Shimakami, R.E. Lanford, and S.M. Lemon Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities Curr. Opin. Pharmacol. 9 2009 537 544
13. C.-S. Chen, C.-T. Chiou, G.S. Chen, S.-C. Chen, C.-Y. Hu, W.-K. Chi, Y.-D. Chu, L.-H. Hwang, P.-J. Chen, D.-S. Chen, S.-H. Liaw, and J.-W. Chern Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase J. Med. Chem. 52 2009 2716 2723
14. G. Manfroni, J. Paeshuyse, S. Massari, S. Zanoli, B. Gatto, G. Maga, O. Tabarrini, V. Cecchetti, A. Fravolini, and J. Neyts Inhibition of subgenomic hepatitis C virus RNA replication by acridone derivatives: identification of an NS3 helicase inhibitor J. Med. Chem. 52 2009 3354 3365
15. S. Kandil, S. Biondaro, D. Vlachakis, A.-C. Cummins, A. Coluccia, C. Berry, P. Leyssen, J. Neyts, and A. Brancale Discovery of a novel HCV helicase inhibitor by a de novo drug design approach Bioorg. Med. Chem. Lett. 19 2009 2935 2937
16. D. Lamarre, P.C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bös, D.R. Cameron, M. Cartier, M.G. Cordingley, A.-M. Faucher, N. Goudreau, S.H. Kawai, G. Kukolj, L. Lagacé, S.R. LaPlante, H. Narjes, M.-A. Poupart, J. Rancourt, R.E. Sentjens, R. St George, B. Simoneau, G. Steinmann, D. Thibeault, Y.S. Tsantrizos, S.M. Weldon, C.-L. Yong, and M. Llins-Brunet An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 426 2003 186 189 (Corrigendum published: Nature 426 (2003) 314) (Pubitemid 37442587)
17. X. Tong, A. Arasappan, F. Bennett, R. Chase, B. Feld, Z. Guo, A. Hart, V. Madison, B. Malcolm, J. Pichardo, A. Prongay, R. Ralston, A. Skelton, E. Xia, R. Zhang, and F.G. Njoroge Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease Antimicrob. Agents Chemother. 54 2010 2365 2370
18. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, R.A. Fridell, M.H. Serrano-Wu, D.R. Langley, J.-H. Sun, D.R. O'Boyle II, J.A. Lemm, C. Wang, J.O. Knipe, C. Chien, R.J. Colonno, D.M. Grasela, N.A. Meanwell, and L.G. Hamann Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
19. S. Altamura, U. Koch, Treating Hepatitis C Viral Infections with Thiosemicarbazone Compounds, U.S. Patent Appl. 2003/0176503 A1, September 18, 2003.
20. R.M. Niles Recent advances in the use of vitamin A (Retinoids) in the prevention and treatment of cancer Nutrition 16 2000 1084 1090
21. R.D. Semba Vitamin A and immunity to viral, bacterial and protozoan infections Proc. Nutr. Soc. 58 1999 719 727
22. A.C. Ross, and C.B. Stephensen Vitamin A and retinoids in antiviral responses FASEB J. 10 1996 979 985 (Pubitemid 26285973)
23. H.N. Green, and E. Mellanby Vitamin A as an anti-infective agent Br. Med. J. II 1928 691 696
24. A.J. Eid, and R.R. Razonable New developments in the management of cytomegalovirus infection after solid organ transplantation Drugs 70 2010 965 981
25. E. De Clercq Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections Clin. Microbiol. Rev. 14 2001 382 397 (Pubitemid 32294676)
26. D. Chattopadhyay, S.K. Mazumdar, T. Banerjee, and T.C.W. Mak Crystal and molecular structure of 4-(N,N-dimethylamino)benzaldehyde thiosemicarbazone J. Cryst. Spectrosc. Res. 18 1988 701 712
27. Y. Yu, L.-R. Lin, K.-B. Yang, X. Zhong, R.-B. Huang, and L.-S. Zheng p-Dimethylaminobenzaldehyde thiosemicarbazone: a simple novel selective and sensitive fluorescent sensor for mercury(II) in aqueous solution Talanta 69 2006 103 106 (Pubitemid 43165509)
28. A.A. Sirotenko Microdetermination of carbon in compounds containing alkali metals Mikrochim. Acta (Wien) 40 1952 30 31
29. J.B. Fenn, M. Mann, C.K. Meng, S.F. Wong, and C.M. Whitehouse Electrospray ionization for mass spectrometry of large biomolecules Science 246 1989 64 71 (Pubitemid 19252085)
30. 13C-NMR spectroscopy Helv. Chim. Acta 64 1981 1969 1984
31. 13C-NMR study of cis-trans isomeric vitamins A, carotenoids and related compounds Helv. Chim. Acta 58 1975 2367 2390
32. ® A: Interferon Alfa-2b, Recombinant, for Injection 2006 Schering Corporation Kenilworth, NJ, USA
33. A. Meager, R. Gaines Das, K. Zoon, and A. Mire-Sluis Establishment of new and replacement World Health Organization International Biological Standards for human interferon alpha and omega J. Immunol. Methods 257 2001 17 33 (Pubitemid 33001230)
34. 55-MurNAc-(Peptide)-GlcNAc] serves as an acceptor in a sorting reaction J. Bacteriol. 184 2002 2141 2147 (Pubitemid 34259663)
35. L. Pickart, J.H. Freedman, W.J. Loker, J. Peisach, C.M. Perkins, R.E. Stenkamp, and B. Weinstein Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells Nature 288 1980 715 717 (Pubitemid 11168529)
36. D.J. Bauer, K.R. Dumbell, P. Fox-Hulme, and P.W. Sadler The chemotherapy of variola major infection Bull. World Health Organ. 26 1962 727 732
37. C.C. García, B.N. Brousse, M.J. Carlucci, A.G. Moglioni, M. Martins Alho, G.Y. Moltrasio, N.B. D'Accorso, and E.B. Damonte Inhibitory effect of thiosemicarbazone derivatives on Junin virus replication in vitro Antivir. Chem. Chemother. 14 2003 99 105 (Pubitemid 36781670)
38. G. Repetto, A. del Peso, and J.L. Zurita Neutral red uptake assay for the estimation of cell viability/cytotoxicity Nat. Protoc. 3 2008 1125 1131
39. C.J. Pfau P.E. Came, L.A. Caliguiri, The Thiosemicarbazones Handbook of Experimental Pharmacology vol. 61 1982 Springer-Verlag Berlin 147 204
40. S.-Y.P. Chang, B.H. Bowman, J.B. Weiss, R.E. Garcia, and T.J. White The origin of HIV-1 isolate HTLV-IIIB Nature 363 1993 466 469 (Pubitemid 23179396)
41. L.M. Finkielsztein, E.F. Castro, L.E. Fabián, G.Y. Moltrasio, R.H. Campos, L.V. Cavallaro, and A.G. Moglioni New 1-indanone thiosemicarbazone derivatives active against BVDV Eur. J. Med. Chem. 43 2008 1767 1773
42. M.R. Grever, S.A. Schepartz, and B.A. Chabner The National Cancer Institute: cancer drug discovery and development program Semin. Oncol. 19 1992 622 638 (Pubitemid 23004840)
43. N. Krieger, V. Lohmann, and R. Bartenschlager Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations J. Virol. 75 2001 4614 4624 (Pubitemid 32381503)
44. H. Nakabayashi, K. Taketa, K. Miyano, T. Yamane, and J. Sato Growth of human hepatoma cell lines with differentiated functions in chemically defined medium Cancer Res. 42 1982 3858 3863 (Pubitemid 12054507)
45. V. Lohmann, F. Körner, J.-O. Koch, U. Herian, L. Theilmann, and R. Bartenschlager Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 285 1999 110 113 (Pubitemid 29307577)
46. S. Ma, J.E. Boerner, C. TiongYip, B. Weidmann, N.S. Ryder, M.P. Cooreman, and K. Lin NIM811, a cyclophilinS200 inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon Antimicrob. Agents Chemother. 50 2006 2976 2982 (Pubitemid 44396401)
47. H.-J. Kim, A. Sharon, C. Bal, J. Wang, M. Allu, Z. Huang, M.G. Murray, L. Bassit, R.F. Schinazi, B. Korba, and C.K. Chu Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro J. Med. Chem. 52 2009 206 213
48. D.C. Quenelle, M.N. Prichard, K.A. Keith, D.E. Hruby, R. Jordan, G.R. Painter, A. Robertson, and E.R. Kern Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses Antimicrob. Agents Chemother. 51 2007 4118 4124 (Pubitemid 350057813)
49. E.R. Kern, N.L. Kushner, C.B. Hartline, S.L. Williams-Aziz, E.A. Harden, S. Zhou, J. Zemlicka, and M.N. Prichard In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication Antimicrob. Agents Chemother. 49 2005 1039 1045 (Pubitemid 40327721)
50. E.R. Kern, M.N. Prichard, D.C. Quenelle, K.A. Keith, K.N. Tiwari, J.A. Maddry, and J.A. Secrist III Activities of certain 5-substituted 4′-thiopyrimidine nucleosides against orthopoxvirus infections Antimicrob. Agents Chemother. 53 2009 572 579
51. R.F. Schinazi, J.-P. Sommadossi, V. Saalmann, D.L. Cannon, M.-Y. Xie, G.C. Hart, G.A. Smith, and E.F. Hahn Activities of 3′-azido-3′- deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1 Antimicrob. Agents Chemother. 34 1990 1061 1067 (Pubitemid 20177356)
52. T.J. Spira, L.H. Bozeman, R.C. Holman, D.T. Warfield, S.K. Phillips, and P.M. Feorino Micromethod for assaying reverse transcriptase of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus J. Clin. Microbiol. 25 1987 97 99 (Pubitemid 17202983)
53. L.J. Stuyver, S. Lostia, M. Adams, J.S. Mathew, B.S. Pai, J. Grier, P.M. Tharnish, Y. Choi, Y. Chong, H. Choo, C.K. Chu, M.J. Otto, and R.F. Schinazi Antiviral activities and cellular toxicities of modified 2′,3′- dideoxy-2′,3′-didehydrocytidine analogues Antimicrob. Agents Chemother. 46 2002 3854 3860 (Pubitemid 35403261)